| Literature DB >> 35239132 |
Dominick Albano1,2, Farah Pragga3,4, Rena Rai2,5, Teresa Flowers6, Prachi Parmar7, Susan Wnorowski8, Evelyn R Hermes-DeSantis2,5.
Abstract
Medical information (MI) professionals are primarily responsible for researching and responding to unsolicited requests for information on their company's product(s). In an effort to set a standard for quality, the Pharma Collaboration for Transparent Medical Information (phactMI) created a code of practice for the provision of medical information to healthcare professionals. This code introduced the term "MI science skills" to describe the expertise required to perform the duties of an MI professional. These skills can be summarized by the acronym DRESS. In order to effectively and efficiently respond to an unsolicited request for information, the MI professional essentially follows five steps: define the question, research the topic, evaluate the evidence, synthesize a response, and share the answer. As this approach mirrors the scientific process for data generation, MI scientist may be a more apt description for this role. This paper explains the rationale behind the term MI scientist and the skills associated with each component of the DRESS approach.Entities:
Keywords: Literature review; Medical information inquiry handling; Medical information practice; Medical information science skills; Medical information service
Mesh:
Year: 2022 PMID: 35239132 PMCID: PMC8964616 DOI: 10.1007/s43441-021-00366-w
Source DB: PubMed Journal: Ther Innov Regul Sci ISSN: 2168-4790 Impact factor: 1.778
Examples of commonly used literature retrieval databases [14–19]
| Database name | Content | Details | Limitations (11) | Vocabulary |
|---|---|---|---|---|
| Public databases | ||||
| Medline [ | More than 26 million references in life sciences with a focus on biomedicine | US National Library of Medicine database. Historically focused on US content, although expanding. Primary component of PubMed | Subscription required; difficult to retrieve references not yet indexed | Indexed with NLM Medical Subject Headings (MeSH®) |
| PubMed [ | Free resource with more than 30 million references. Does not contain full text but might link to full text | Considered a partner with Medline. Recently updated to be mobile friendly | Does not contain full text but might link to full text. Excludes most of the literature that is not peer reviewed (gray literature) which may result in an incomplete search | MeSH or free text (open vocabulary) |
| Google Scholar [ | Literature in any language uploaded to the Internet in electronic format | From parent company Google | Compared to other databases, results can be skewed by number of visitors rather than relevance, less frequently updated | Natural language |
| Subscription-based databases | ||||
| EMBASE [ | More than 37 million records, including more than 6 million records and close to 3000 journals not covered by Medline | Owned by Elsevier, greater focus ex-US so could be considered companion to Medline/Pubmed for global coverage. Extensive coverage of congresses and medical device literature | Only available by subscription | Indexed with embase indexing and emtree |
| OVID [ | More than 6,000 eBooks, over 1400 premium, peer-reviewed journals-with no embargoes (with one exception—science). Over 100 bibliographic and full-text databases | Owned by Wolters Kluwer. Provides database offerings in Chinese, French, and Spanish. Offers a dedicated work area into which a researcher can organize and manage material | Boolean searches default to keyword searches which may result in less robust retrieval results | Natural language searching |
| Web of science [ | Web of science is a platform consisting of several literature search databases (including Medline) Includes > 21,419 journals + books and conference proceedings. Over 79 million records More than 119,000 books Over 220,000 conferences covered | Held by clarivate analytics. Has language and geography-focused options, for example, Chinese Science Citation database, Russian Science Citation Index, and Korean Journal Index. The core collection serves as the standard dataset underpinning journal impact metrics found in the journal citation report | Only available by subscription | No controlled vocabulary. Keyword fields include author keywords and “Keywords +” which are extracted from the titles of cited articles. Controlled indexing is provided for institution affiliations |
Study designs, levels of hierarchy, and important considerations [22–24]; [35–37])
| Level | Types of Study Designs/Trials | Description | Considerations |
|---|---|---|---|
| 1 | Systematic reviews of randomized controlled trials | An integration of statistically evaluated results that come from previously conducted studies. This type of design considers an individual study as the unit of analysis vs the individual patient. | •Systematic reviews should be used over individual trials when available; highest standard of literature •Could be useful when past studies may have had inconsistent results and included smaller number of subjects |
| 2 | Randomized trial or observational study with dramatic effect | A trial with both an experimental (interventional) and a control (placebo or standard treatment) group in which patients are randomly assigned; can be parallel or cross-over Real world evidence or comparative effectiveness trials may be included | •Randomized trials are considered the gold standard, strongest study design, and highly reliable for majority of medical questions •Sample should be representative of the population that the intervention would apply to •Real World Evidence studies often seek effectiveness data in clinical settings, accounting for variables, such as adherence, switching, discontinuing, and/or concomitant medications. These studies are considered complementary to randomized controlled trials as they often fill data gaps left by randomized trials |
| 3 | Non-randomized controlled cohort/follow-up study | Strongest observational study where subjects that are free of the outcome are divided into groups: one that is exposed to the factor of interest and the other that is not exposed. Groups are not randomly assigned in this design. Both groups need to have standardized eligibility criteria and outcome assessments | •Reliable and applicable for questions related to diagnosis, prognosis, and incidence. May not be best for questions of efficacy •A limitation is that these studies tend to be lengthy and a large number of subjects are involved •There could be a lack of randomization, difficulty in identifying controls, and hidden confounding factors linked to the exposure |
| 4 | Case-series, case–control studies, or historically controlled studies | Case control: helps to determine if a particular exposure is associated with an outcome. Patients with a specific outcome of interest (disease or condition) are matched with patients that do not have that same outcome of interest. Investigators look back in time to determine frequency of exposure between the two groups Cross-section: examines the relationship between health-related characteristics or diseases and other variables of interest that exist in a defined population at a single point in time Case report: descriptive report of an observation made on a specific patient or on multiple patients (i.e., adverse event). Retrospective in nature | •Less reliable due to potential for recall bias and retrospective data collection (i.e., inconsistency in patient records) •This design might be beneficial when there is a long-lag time between exposure and outcome |
| •Study design helps to establish association but not causality. Disadvantages are recall bias and inequitably distributed confounders | |||
| •May be challenging to interpret outcomes due to multiple factors; however, could be useful if other types of studies are unavailable | |||
| 5 | Mechanism based reasoning | •Regardless of the medical question being addressed, this is the least reliable information and based mainly on expert opinion without explicit critical appraisal |
Based on the quality of any of the studies, the level of evidence can be shifted down. It can also be shifted up if there is a large/very large effect size
Questions to ask when summarizing a clinical trial [26–28]
| Section | Questions | Comments |
|---|---|---|
| Introduction | What is the objective of the study? | This sets the stage for everything else in the study |
| Methods | What is the study design? | |
| Are inclusion criteria adequate? | The predefined criteria for patients to participate in the clinical trial should be clearly specified and appropriate so that the study is clinically relevant to the question being asked | |
| Are exclusion criteria adequate? | The primary goal of exclusion criteria is to ensure patient safety. Investigators can use this criterion to exclude patients that might have a higher risk of increased adverse events or other safety issues. On the other end, exclusion criteria shouldn’t be so restrictive that the study results are not clinically relevant to a specific patient population that would require treatment | |
| Is the study randomized? | Randomized trials are considered the gold standard and highly reliable for majority of medical questions | |
| Is the length of the study appropriate to show effect? | If a study hasn’t been conducted for an appropriate amount of time, then a treatment effect may not be seen when in fact there is potential for this effect | |
| Are dosages and treatment regimens appropriate? | The dosage and treatment regimen being used in the study should be representative of what is typically observed for the specific indication being addressed | |
| Is the study blinded? | Compared to a single-blinded study, a double-blinded study makes an effort to prevent investigator and subject bias. If there are barriers to blinding, then that could be a major limitation of the study | |
| Are the endpoints standard, validated, or accepted? | The test or measurement of evaluation used in the study to accurately assess the primary outcome needs to be either formally validated or an accepted practice. Otherwise, even statistically significant results may not be relevant and could leave a doubt in the reader's mind | |
| Statistics | Are the statistics appropriate? | |
| Is power set and/or met? | Power, or the risk of avoiding a type II error, is critical for evaluating a study. The lowest acceptable power is 80%, if the power is not set or met, it may mean that the study does not have enough enrolled subjects to detect a difference | |
| Delta | The clinically relevant difference being sought. There should be an explanation as to why the number was selected | |
| Are appropriate statistical tests used for type(s) of data | The statistical test is selected based on the type of data collected for the endpoint of the study | |
| Results | Demographic | |
| Did randomization result in similar groups? | After the subjects are randomized, each study group should have similar baseline characteristics and demographics. If there is significant inequality between treatment groups, it is unclear if the results observed were due to this difference in groups or the actual study drug | |
| How similar is the study group to typical patient group with the disease? | The group being studied should appropriately reflect the demographic characteristics (i.e., age, gender, and race) of the patient population with the disease state | |
| Efficacy results | The meat of the study. This section needs to be evaluated for both statistical significance and clinical relevance. All endpoints mentioned in the methods should be accounted for | |
| Safety results | As a balance to the efficacy, safety data need to be evaluated as well | |
| Conclusions | ||
| Are they supported by the results? | The results and data should match what the author is stating as the conclusions of the study. If there is a discrepancy between the results and the conclusion, it could lead the study to be potentially questionable | |